"Dalteparin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Concept/Terms
Fragmin- Fragmin
- Pfizer Brand of Dalteparin Sodium
- Fragmine
Below are MeSH descriptors whose meaning is more general than "Dalteparin".
Below are MeSH descriptors whose meaning is more specific than "Dalteparin".
This graph shows the total number of publications written about "Dalteparin" by people in Harvard Catalyst Profiles by year, and whether "Dalteparin" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1999 | 0 | 2 | 2 |
2001 | 1 | 2 | 3 |
2003 | 0 | 1 | 1 |
2004 | 1 | 0 | 1 |
2005 | 2 | 0 | 2 |
2007 | 2 | 1 | 3 |
2008 | 1 | 1 | 2 |
2009 | 0 | 1 | 1 |
2012 | 0 | 1 | 1 |
2015 | 1 | 1 | 2 |
2017 | 1 | 0 | 1 |
2018 | 1 | 0 | 1 |
2019 | 1 | 0 | 1 |
2020 | 1 | 1 | 2 |
2021 | 1 | 2 | 3 |
2022 | 0 | 2 | 2 |
Below are the most recent publications written about "Dalteparin" by people in Profiles.
-
Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial Haematologica. 2022 07 01; 107(7):1567-1576.
-
Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study. Eur J Cancer. 2022 04; 165:136-145.
-
Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer. Thromb Haemost. 2022 May; 122(5):796-807.
-
Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study. J Thromb Haemost. 2021 11; 19(11):2751-2759.
-
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis. Mayo Clin Proc. 2022 02; 97(2):308-324.
-
In cancer-associated VTE, apixaban was noninferior to dalteparin for recurrence and did not increase major bleeding. Ann Intern Med. 2020 08 18; 173(4):JC21.
-
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med. 2020 04 23; 382(17):1599-1607.
-
Cost-effectiveness of edoxaban versus dalteparin for the treatment of cancer-associated thrombosis. J Thromb Thrombolysis. 2019 Oct; 48(3):382-386.
-
Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study. Thromb Haemost. 2018 Sep; 118(9):1668-1678.
-
Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. Thromb Haemost. 2018 Aug; 118(8):1439-1449.